Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label rollover study of long-term VX-770 in cystic fibrosis
2009-012997-11Phase 3Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Apr 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ivacaftor in cystic fibrosis (CF), sponsored by Vertex Pharmaceuticals. Primary endpoint: Long-term safety of ivacaftor. Started Apr 2010; status: completed.
02
Drugs
ivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on 2009-012997-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012997-11.